Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	680.85	464.37	250.31	83.8	22.81
Revenue Growth (YoY)	46.62%	85.52%	198.69%	267.35%	37537.14%
Cost of Revenue	293.08	213.89	155.16	96.88	67.68
Gross Profit	387.77	250.48	95.16	-13.08	-44.86
Selling, General & Admin	504.49	409.86	358.78	272.61	186.36
Operating Expenses	504.49	409.86	358.78	272.61	186.36
Operating Income	-116.72	-159.38	-263.63	-285.69	-231.23
Interest & Investment Income	42.52	20.34	7.38	1.57	4.24
Pretax Income	-74.2	-139.04	-256.25	-284.12	-226.99
Income Tax Expense	0.47	0.64	0.01	0.01	0.01
Net Income	-74.68	-139.67	-256.26	-284.13	-227.01
Net Income to Common	-74.68	-139.67	-256.26	-284.13	-227.01
Shares Outstanding (Basic)	103	96	94	81	70
Shares Outstanding (Diluted)	103	96	94	81	70
Shares Change (YoY)	7.56%	1.95%	15.75%	15.47%	27.50%
EPS (Basic)	-0.72	-1.46	-2.72	-3.50	-3.23
EPS (Diluted)	-0.72	-1.46	-2.72	-3.50	-3.23
Free Cash Flow	-73.5	-124.47	-270.96	-259.87	-230.34
Free Cash Flow Per Share	-0.71	-1.30	-2.88	-3.20	-3.27
Gross Margin	56.95%	53.94%	38.02%	-15.60%	-196.66%
Operating Margin	-17.14%	-34.32%	-105.32%	-340.90%	-1013.58%
Profit Margin	-10.97%	-30.08%	-102.37%	-339.04%	-995.07%
Free Cash Flow Margin	-10.79%	-26.80%	-108.25%	-310.10%	-1009.69%
EBITDA	-116.21	-158.85	-262.97	-285.16	-230.7
EBITDA Margin	-17.07%	-34.21%	-105.06%	-	-
D&A For EBITDA	0.51	0.53	0.66	0.53	0.53
EBIT	-116.72	-159.38	-263.63	-285.69	-231.23
EBIT Margin	-17.14%	-34.32%	-105.32%	-	-
Revenue as Reported	680.85	464.37	250.31	83.8	22.81
Advertising Expenses	101.2	92.2	85.8	82.5	36.3

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q